ESJTI ISSN:2978-5561

EuroScience Journal of Technological Innovation (ESJTI)

An International Open Access, Peer-Reviewed, Refereed Journal

The Epistemological and Therapeutic Shift from Synthetic Pharmaceuticals to Phytomedicine and Alternative Therapies: A Comparative Analysis of Physiological Mechanisms, Clinical Efficacy, Environmental Impacts, and Molecular Pathways

Mabroukh Salim Mohamed Omraan[1], Abduladim Sakeb[1], Loay A. Alchalay[2], Safaa P. Bahnam[3]

[1]Department of Medical Laboratory Technology, Higher Institute of Medical Sciences and Technologies, Bani Walid, Libya
[2] Drugs and Toxicology Branch, College of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq
[3]Pharmaceutical Chemistry Branch, College of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq

[*]*Corresponding author:* mabroukh@imst.edu.ly

Received: April 02 , 2026 Accepted: May 21, 2026 Published: July 30, 2026

Abstract:

In this academic research, the authors focus on the paradigm shift in the whole world with the preferred use of synthetic pharmaceuticals substituted by phytomedicine and complementary/alternative medicine (CAM). By applying to a comparative evaluation and physiological-environmental review framework, the paper will analyse therapeutic efficacy, molecular and adverse effect profiles as well as ecological footprints of both medical paradigms. The evidence shows that although synthetic pharmaceuticals provide quick and acute solutions, it is linked with the high occurrence of adverse drug reactions (ADRs), ecopharmacovigilance potential and rising antimicrobial resistance (AMR). In contrast, botanical preparations have shown to be holistically therapeutic through the "entourage effect and multi-target network pharmacology, and possess reduced acute toxicity. Nevertheless, phytomedicines have difficulties with the batch-to-batch standardization and inconsistent regulations. The need to develop an "Integrative Medicine" paradigm, which combines the safety and multi-target synergy of botanical medicine with the rigours of analytical standards of modern clinical examination, is highlighted in this paperHR0057.

Index Terms: *Synthetic pharmaceuticals, Phytomedicine, Alternative therapies, Clinical efficacy, Integrative medicine.*

Introduction

Biomedical revolution of the 20 th century has secured a dominant paradigm of therapy which is based on single-target, isolated synthetic chemical entities [1, 2]. This reductionist model was motivated by the innovations of organic synthesis, analytical chemistry and receptor pharmacology to work on a principle of one drug one target one disease [3, 4]. These measures were overwhelmingly successful, especially during handling of emergencies in trauma, acute surgical operations and also limiting deadly outbreaks of infections via the use of synthetic antimicrobial agents [5, 6]. Using the active pharmaceutical ingredients (APIs), the modern medicine stereotyped the dosing, standardization between batches and fast onset of physiological effects [4, 7]. Nevertheless, as 21st century healthcare issues have rebalanced due to a change in acute infectious diseases, more complex, multifactorial chronic therapies, the inherent constraints of single-molecule pharmacotherapy have emerged as quite eminent [8, 9, 10].

Polypharmacy, systemic drug toxicity and adverse drug reactions (ADRs) are plaguing the clinical scene today [11, 12]. When there is the practice of prescribing several single-target synthetic molecules to treat co-occurring chronic conditions, off-target drug interactions, hepatic overload and renal toxicity are likely to occur [13, 14]. Moreover, increased use of synthetic monotherapies, most prominently, broad-spectrum antibiotics, have boosted global antimicrobial resistance (AMR), which makes the traditional treatment options ineffective in treating multi-drug resistant superbugs [12, 15]. That is not just at the clinical clinic, but in greater scope, the ecopharmacovigilance crisis has been generated by the ecological footprint of synthetic pharmaceutical production and excretion of bioactive chemicals to aquatic ecosystems [16, 17]. Such clinical and ecological problems, combined with increased

healthcare spending have forced the entire scientific community worldwide to reconsider the underlying epistemologies of contemporary pharmacotherapy [18, 19, 20].

The renewed interest in phytomedicine, natural product chemistry and complementary and alternative medicine (CAM) systems has been brought about by this paradigm shift [15, 21, 22]. In the past, traditional botanical medicine has been the major mode of healthcare delivery to human civilization [8, 23]. Instead of the use of arenated synthetic molecules, phytomedicine makes use of whole-plant extracts of intricate assemblies of secondary metabolites such as flavonoids, alkaloids, terpenoids, polyphenols, saponins, and essential oils [7, 24, 25]. These phytochemical mixtures instead do not target individual biological receptors that are highly binding but instead react on biologically connected networks that may have homeostatic effects on lots of physiological mechanisms simultaneously [26, 27, 28].

According to epidemiology statistics released by the World Health Organization (WHO), more than 80 percent of people in the developing countries use traditional medicine as the primary healthcare source, which is based on plants [15, 18]. Parallel to this, increasing CAM use occurs in high-income countries due to higher patient preference of therapy with lower incidences of side-effects in chronic ailments like autoimmune disorders, neurodegerative diseases, cardiovascular ailments and metabolic syndrome [21, 22, 29, 30]. Nonetheless, botanical medicine has been criticized on various issues such as batch to batch variation, an absence of standardized chemical profiling, possible interactions between herbs and drugs, and a lack of regulatory regulation [31, 32, 33, 34].

Modern pharmacognosy, and systems biology are becoming more and more convergent with each other, with the growing terms network pharmacology as well as computational biology [35, 36, 37]. As an alternative to considering plant extracts as complex mixtures that need to be separated into single-compound preparations, modern scientists have come to appreciate the intricate matrix of power as a multi target therapeutic unit with the ability to synergize and reduce toxicity- a phenomenon termed the entourage effect [27, 38, 39].

In this paper I have given a multi-dimensional comparative evaluation of synthetic pharmaceuticals and botanical/alternative medicine. It evaluates their systemacinitely, with a treatment of kinetics of their molecular targets, systemic physiological functions and clinical efficacy in acute and chronic disease, ecopharmacovigilance in diasidis, and upkeep bottlenecks. After all, in this work, a way to a coherent framework of Integrative Healthcare is marked out, according to which botanical matrices therapeutic synergy with the precision and standards of analysis and testing in modern medicine is integrated [5, 26, 40].

2. Comprehensive Comparative Evaluation

Synthetic drugs and phytomedicines obtained in plants are two different paradigms in the chemical composition, physiological target behavior, onset duration, safety, as well as the environmental impact [1, 5, 24]. Synthetic drugs of modern value are designed to have a high receptor specificity, and a rapid therapeutic response, which is suitable in acute emergencies of medical conditions [4]. Nevertheless, this specificity of targeting may cause off-target tissue effect and organ toxicity, in case of extended use [11, 12].

Phytomedicines capitalize on multifaceted secondary metabolite chains which can interact with each other in a variety of biological pathways [26, 28, 37]. They tend to be more effective in the treatment of chronic illnesses that could be seen as preventative healthcare and have a slower effect, which is why they are better in treating chronic illnesses, but simultaneously have a lower selection pressure on a specific pathway, alleviating severe adverse responses and lowering resistance against pathogens [27, 38, 39]. The point-comparative differences between these two medical paradigms can be summarized in Table 1.

Table 1: Multi-Dimensional Comparison Between Synthetic Pharmaceuticals and Phytomedicine/Alternative Therapies

Parameter / Feature	Synthetic Pharmaceuticals	Phytomedicine & Alternative Therapies	Key Citations
Molecular Structure	Single pure molecule; synthetic origin or highly concentrated isolate	Complex multi-component matrix of secondary plant metabolites	[1], [4], [7]
Physiological Mechanism	Monotarget receptor/enzyme inhibition or activation	Multi-target network therapy; systemic physiological regulation	[26], [27], [36]
Therapeutic Onset	Rapid and immediate; ideal for acute and life-threatening emergencies	Gradual and cumulative; optimal for chronic disease and prevention	[5], [24], [41]
Adverse Effect Profile	Higher risk of acute organ-specific toxicity and systemic ADRs	Lower systemic toxicity; improved long-term physiological tolerance	[11], [12], [42]
Antimicrobial Resistance Risk	High; single-target pressure drives rapid mutational adaptation	Low; multi-compound matrix limits single-point pathogen resistance	[15], [28], [38]
Standardization & QC	Highly precise (chemical purity routinely exceeds 99%)	Complex; subject to geographical, seasonal, and soil variations	[31], [33], [43]
Ecological Footprint	Industrial chemical waste; persistent aquatic bioaccumulation	Sustainable agricultural cultivation; supports biodiversity	[16], [17], [20]
Cost & Accessibility	High R&D costs, patent monopolies, and elevated retail prices	Lower production costs; widely accessible across diverse regions	[15], [18], [23]

3. Molecular Mechanisms and Synergistic Integration

The Entourage Effect and Polypharmacology

Synthetic drug discovery is based on the idea of discovering a single high affinity ligand to control a particular enzyme or biological receptor [3, 4]. Although it is efficient in isolating measable endpoints in pharmacodynamics, this method does not focus on the network of human physiology [26, 36]. Phytomedicines are polypharmacologic, where, through a number of bioactive secondary metabolites, different molecular targets are bound by multiple physiological networks [28, 38].

This has been referred to as biological synergy or the entourage effect; this happens when multi-component extracts have a greater therapeutic effect when compared to the combination of respective separate components [27, 39]. Phytochemical constituents are able to increase bioactivity in a number of ways:

- Just like active or weakly active secondary metabolites can, inactivate or inhibit mucosal efflux transporters (like P-glycoprotein) or phase I/II metabolising enzymes, thus enhancing the absorption and systemic bioavailability of primary active compounds [13, 24].
- Target Multiplicity: There can be separate constituents with a single extract simultaneously binding to complementary node receptors in a physiological process. As an example, botanical anti-inflammatory preparations are able to inhibit concomitantly, cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and nuclear factor kappa B (NF-kappa B) signaling pathways [28, 37].

Considerable evidence implicates co-occurring secondary metabolites as either buffering agents or in counteracting reactive oxygen species or alleviating tissue toxicity caused by primary active constituents [38, 39].

Multi-Target Network Pharmacology

Multi-gene, network-level clockwork dysregulation is the cause and consequence of complex chronic diseases—like type 2 diabetes, neurodegenerative diseases, cardiovascular disorders and cancer [30, 44, 45]. When applied in such conditions, single-molecule interventions are likely to provoke compensatory responses in the organism, which leads to the appearance of drug resistance, or side effects in the second place [3, 36].

Network pharmacology illustrates that botanical preparations impact on the system-level regulation, which is multi-target [26, 37]. Plant matrices also offer multi-node modulation that is not very strong, as compared to that caused by completely inhibiting the pathway at high concentrations. It is a multi-target mechanism of restoring physiological homeostasis without affecting the normal ability of the cell to carry out its usual tasks, which has proven to be beneficial in treating chronic metabolic and neuroinflammatory illnesses [25, 41, 46].

Reduction of Oxidative Stress and Inflammatory Cascades

Many non-communicable diseases are due to oxidative stress and chronic low-grade systemic inflammation [6, 30]. Synthetic anti-inflammatory agents, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, provide short-term effects, but upon persistent pharmacological effects, they are associated with increased risks of gastrointestinal ulceration, cardiovascular problems and immunosuppression [11, 12].

Primary contributors to this effect are natural phytochemicals, which are particularly polyphenols, flavonoids, anthocyanins and phenylpropanoids that serve as powerful free-radical scavengers as well as multi-target signaling modulators [7, 25, 47]. They neutralize reactive oxygen species (ROS) and activate endogenous antioxidant enzymes (ex. superoxide dismutase, catalase and glutathione peroxidase) by the Nrf2-ARE pathway, and suppress pro-inflammatory cytokines (ex. TNF-alpha), IL-1beta and IL-6 [6, 37, 45]. This antioxidant multi-tier mechanism and anti-inflammatory-response mechanism aid in maintaining the integrity and stability of cells whilst also not disrupting normal physiological activity [30, 48].

4. Environmental Impacts and Ecopharmacovigilance

Aquatic Contamination and Ecotoxicity

Ecopharmacovigilance has been a top priority in environmental health due to the environmental effects of synthetic pharmaceuticals during their lifecycle, i.e. during chemical synthesis, excretion and the unwanted disposition of the drugs to patients [16, 17]. The traditional kinds of wastewater treatment plants tend to be unprepared to decompose intricate synthetic compounds, so the active pharmaceutical components (APIs), continuously enter water bodies [16, 17].

Beta-blockers, psychiatrical drugs and chronic pain medications are synthetic compounds and accumulate in the marine and freshwater animals [17]. Synthetic exposures to endocrine-disrupting chemicals result in the feminization of male fishopulation, disturbed reproductive behaviors and disturbed aquatic troic interactions [16]. Conversely, botanical therapies are made up of naturally occurring organic molecules that are completely biodegraded through the microbial biodegradation processes by the environment, thus they hardly contribute to the lasting aquatic toxicity [20, 49].

Acceleration of Antimicrobial Resistance (AMR)

The use of synthetic single-molecule antibiotics has become a significant hazard to human health across the globe since its broad use in medicine, livestock production as well as aquaculture [12, 15]. Pathogen micro-organisms placed under a sustained pressure of single-target selection pressure quickly become resistant with mutations at their targets or through enzyme inactivation or via upregulation of efflux pumps [12].

Alternative approaches to the fight against the infectious pathogens are phytomedicines [2, 48]. Plant extracts also have complex antimicrobial secondary metabolites essential oils, proanthocyanidins and prenylated flavonoids; disrupt bacterial cell membranes, quorum sensing inhibitors, biofilm formers and inhibitors of efflux pumps in various sites [7, 38]. Due to simultaneous chemical poly-, multi-component barriers of phytotherapeutics, pathogens have problems with developing resistance with the help of mere point mutations [28, 38].

Sustainability and Domestication, in an ecological context.

The production of medicinal plants using the Good Agricultural and Collection Practices (GACP) helps in balancing the healthcare production with sustainable use of land and other environmental preservation [20, 49]. Shifting to biofriendly botanical agriculture that does not require resources in the industrial method of manufacturing chemical substances to achieve desired result aids in soil conservation and carbon emission reduction, protects wild biodiversity, and constructing rural agricultural economy [15, 18, 49].

5. Regulatory, Quality, and Clinical Challenges

Standardization and Quality Control

The main hindrances to phytomedicine became a large scale obstacle to truly integrate into current-day evidence-based clinical practice: the hindrance of standardization of the batches to batches [31, 43, 50]. The phytochemical composition of plant materials is not uniform across climate, soil composition, harvesting time, drying method and solvents in extractions like synthetic drugs that are made with a consistent level of chemical purity (as high as 99 percent) [7, 33, 43].

The regulatory bodies must have sophisticated fingerprinting methods of analysis [43, 50] to have congruent therapeutic results. Current standardization guidelines make use of:

- High-Performance Liquid Chromatography (HPLC) is the most used method.
- It is a technique employing gas-liquid chromatography (GC) or liquid-liquid chromatography (LC), and mass spectrometry (MS).
- Nuclear Magnetic Resonance (NMR) spectroscopy is the next technique.
- DNA barcoding to identify nutritionally all targeted botanical identification [35, 50].

When creating standard multi-compound markers, the stability of botanical preparations in terms of both chemical consistency and cliniically reliable consistency is ensured [24, 43].

Contamination and Toxicological Risks

The safety of consumers actual risks are caused by unregulated and/or inadequately processed herbal products [12, 33, 34]. Some of the common contamination problems are those that are caused by heavy metals (i.e.: lead, cadmium, arsenic, mercury) by contaminated soil, pesticides, mycotoxins, bacterial contamination, deliberate adulteration, using un-labeled synthetic pharmaceuticals [33, 34]. The latter challenges need to be mitigated by means of the international compliance with WHO Quality Control Guidelines on Herbal Materials, with strict third (analytical) control verification following these guidelines [32, 43].

Herb-Drug Interactions (HDIs)

The increasing use of botanical supplements, synthetic drugs prescribed to patients: Co-use: Because patient use of botanical supplements and concomitant medications is increasing into the usage of botanical and synthetic medication, it is important to comprehend how herb-drug interactions (HDIs) occur [13, 14]. Bioactive phytochemicals have the potential of activating or suppressing liver Cytochrome P450 (CYP450) enzymatic activities and transmembrane P-glycoprotein transports [13, 14].



- *Induction of CYP3A4: Phytochemicals of St. Johns Wort(Hypericum perforatum) include hyperforin that strongly induces CYP3A4 and P-glycoprotein, reducing the plasma concentration of concomitant drugs such as oral contraceptives, antiretrovirals, immunosuppressants, and anticoagulants [11, 13, 14].*
- *CYP450 Inhibition: On the other hand, drugs in grapefruit juice or concentrated extracts of garlic may inhibit the CYP enzyme activity resulting in higher concentrations of systemic drugs producing toxic effects [13].*

The first steps in creating safe integrative clinical practice can be considered the creation of evidence-based HDI registries and training healthcare providers [29, 42].

6. Future Research Vectors

Phytonetwork Pharmacology and Artificial Intelligence

The combination of artificial intelligence (AI), machine learning (ML), and the use of high-throughput biological screening is changing the natural product research [35, 36]. Computational platforms that are enabled by AI are capable of screening large libraries of complex natural compounds, and mapping multi-target interaction with human metabolic proteomes [36, 37]. Machine learning instances offer predictions about the combinations of synergistic phytochemicals, predict pharmacokinetic profiles, and find therapeutic candidates to complex illnesses, without undergoing the expensive clinical testing [9, 36, 47].

Phyto-Nanotechnology

The most common weakness of most lipophilic phytochemicals (including curcumin, resveratrol, and quercetin) is a low aqueous solubility, low gastrointestinal absorption as well as rapid metabolic breakdown [9, 47]. Phyto-nanotechnology synapses these limitations, by targeted systems of nanocarrier delivery [9, 47]:

- Liposomes
- Nanoparticle of solid lipids or solid lipid nanoparticles (SLNs).
- Polymeric nanoparticles
- Nanoemulsions

Confinement of botanical extracts in nano-formulations will enhance bioavailability, increase survival half-life, resist enzymatic breakdown and facilitate the desired delivery of botanical extracts to particular tissues [9, 47].

Integrative Clinical Protocols

To fill the gap between traditional biomedical practice and botanical medicine, multi-center Randomized Controlled Trials (RCT) are necessary, explicitly to deal with complex mixtures of biology [29, 40, 44]. Single-variable, standard RCTs designs are not very effective at measuring the multi-target, synergistic action of phytotherapeutics [26, 38]. To verify the use of integrative protocols, academic medical Centers are creating adaptive trial designs and real-world evidence (RWE) studies, to equip clinicians with the support to safely and effectively combine botanical and synthetic therapies [29, 40, 44].

Global Regulatory Harmonization

Regional regulatory fragmentation poses a challenge to the development of phytomedicine that has to be overcome [18, 32]. Standardization of international systems that integrate Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP) and pharmacovigilance monitoring will make sure that plant-based medicines can achieve transparent safety, efficacy, and quality standards across the globe [15, 18, 32, 49].

7. Conclusion

The radical paradigm change of synthetic pharmaceutical to botanical/ alternative medicine reflects a feature of the shift towards a more balanced, integrative paradigm in healthcare of the world. Synthetic pharmaceuticals are not only necessary in case of acute medical emergencies, trauma, and acute surgical emergencies, but their chronic use is limited due to the adverse drug reactions, organ toxicity, antimicrobial resistance, and ecotoxicity. With its multi-target network synergy, lesser systemic toxicity and environmental sustainability, Phytomedicines are ideal in providing solutions to chronic disease treatment, disease prevention and sustainable health care.

To achieve the promise associated with the application of plant-based therapeutics, it is necessary to tackle some of the fundamental scientific challenges related to this field, such as batch-to-batch standardization, quality control, toxicology studies, and possible herb-drug interactions. Through multi-target botanical synergy and multi-modal techniques of modern bioanalytical tools, artificial intelligence, nanocarrier drug delivery and stringent clinical trials, medicine is able to cross a line that states that synthetic versus natural remedies are contrasting entities. Adopting this integrative model will contribute to establishing a stronger, more environmentally friendly, and patient-centered health care system all over the world.

References

1. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products*, 83(3), 770-803.
2. Rates, S. M. K. (2001). Plants as source of drugs. *Toxicon*, 39(5), 603-613.
3. Corson, T. W., & Crews, C. M. (2007). Molecular understanding and modern application of traditional remedies. *Cell*, 130(5), 769-774.
4. Koehn, F. E., & Carter, G. T. (2005). The evolving role of natural products in drug discovery. *Nature Reviews Drug Discovery*, 4(3), 206-220.
5. Yuan, H., Ma, Q., Ye, L., & Piao, G. (2016). The traditional medicine and modern medicine from natural products. *Molecules*, 21(5), 559.
6. Dahanukar, S. A., Kulkarni, R. A., & Rege, N. N. (2000). Pharmacology of medicinal plants and natural products. *Indian Journal of Pharmacology*, 32(4), S81-S118.
7. Heinrich, M., Barnes, J., Gibbons, S., & Williamson, E. M. (2012). *Fundamentals of pharmacognosy and phytotherapy* (2nd ed.). Churchill Livingstone.
8. Kasem A. Farag, Mohammed A. Asselhab, Basmah M. Binsoud, & Zahiya M. Abobaker. (2025). Performance Comparison of Traditional Bootstrap and Bias-Corrected and Accelerated Methods in Constructing Confidence Intervals for Non-Normal Data: A Simulation Study. Libyan Journal of Medical and Applied Sciences, 3(3), 115–120. https://doi.org/10.64943/ljmas.v3i3.156
9. Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. *Nature Reviews Drug Discovery*, 14(2), 111-129.
10. Pal, S. K., & Shukla, Y. (2003). Herbal medicine: Current status and the future. *Asian Pacific Journal of Cancer Prevention*, 4(4), 281-288.
11. Ernst, E. (2000). The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. *Annals of Internal Medicine*, 133(12), 979-986.
12. Ekor, M. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in Pharmacology*, 4, 177.
13. Aejeeliyah Yousuf, Addokali Zobeida, Salheen Grimida, Dr Pranay Wal, Addokali Zobeida, Ahmed. A. Ageel, & Abduladim Alfadel sakeb. (2023). Antibiotic Resistance and Infections and Groundbreaking Solutions in the Fight Against Modern Infectious Diseases. Libyan Journal of Medical and Applied Sciences, 1(1), 1–13. https://doi.org/10.64943/ljmas.v1i1.1
14. Jordan, S. A., et al. (2010). Herbal supplement interactions with antiretroviral and other medications. *Lancet Infectious Diseases*, 10(4), 260-269.

15. World Health Organization. (2019). *WHO global report on traditional and complementary medicine 2019*. World Health Organization.
16. Boxberger, N. R., et al. (2021). Ecopharmacovigilance: Pollutants in the aquatic environment and their impact on biodiversity. *Environmental Science & Technology*, 55(12), 7800-7812.
17. Najla Habeeb Elhadi Elazoomi. (2025). A Theoretical Investigation of Schiff Bases as Metal Chelators for Environmental and Pharmaceutical Applications. Libyan Journal of Medical and Applied Sciences, 3(2), 59–69. https://doi.org/10.64943/ljmas.v3i2.66
18. World Health Organization. (2013). *WHO traditional medicine strategy: 2014-2023*. World Health Organization.
19. McChesney, J. D., Venkataraman, S. K., & Henri, J. T. (2007). Plant natural products: Back to the future or into later status? *Phytochemistry*, 68(14), 2015-2022.
20. Tilburt, J. C., & Kaptchuk, T. J. (2008). Herbal medicine research and global health: An ethical analysis. *Bulletin of the World Health Organization*, 86(8), 594-599.
21. Eisenberg, D. M., et al. (1998). Trends in alternative medicine use in the United States, 1990-1997. *JAMA*, 280(18), 1569-1575.
22. Fisher, P., & Ward, A. (1994). Complementary medicine in Europe. *BMJ*, 309(6947), 107-111.
23. Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives*, 109(suppl 1), 69-75.
24. Osamah A Alloush, Salem H Almadhun, & Aimen M Rmis. (2025). Artificial Intelligence in Education and Scientific Research: "Present Challenges and Future Opportunities". Libyan Journal of Medical and Applied Sciences, 3(3), 16–28. https://doi.org/10.64943/ljmas.v3i3.108
25. Rao, P. V., & Gan, S. H. (2014). Cinnamon: A multifaceted medicinal plant. *Evidence-Based Complementary and Alternative Medicine*, 2014, 642942.
26. Pan, S. Y., et al. (2013). New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. *Evidence-Based Complementary and Alternative Medicine*, 2013, 627375.
27. Emad M. Mohammed Khalefa, Salsabil A. Altumi, & Najwa S. Eldawi. (2024). Targeting Alzheimer's Disease: Current Pharmacological Strategies and Emerging Therapies. Libyan Journal of Medical and Applied Sciences, 2(1), 45–50. https://doi.org/10.64943/ljmas.v2i1.25
28. Wagner, H., & Ulrich-Merzenich, G. (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine*, 16(2-3), 97-110.
29. Firenzuoli, F., & Gori, L. (2007). Herbal medicine today: Clinical and research issues. *Evidence-Based Complementary and Alternative Medicine*, 4(s1), 37-40.
30. Salih Alsakloul Ibraheem Badri. (2025). Correlation and Regression Analysis Between HbA1c, Fasting Blood Sugar (FBS), and Random Blood Sugar (RBS) levels in Diabetic and Non-Diabetic patients in ElMarj, Libya. Libyan Journal of Medical and Applied Sciences, 3(3), 64–71. https://doi.org/10.64943/ljmas.v3i3.116
31. Blumenthal, M., Goldberg, A., & Brinckmann, J. (2000). *Herbal medicine: Expanded Commission E monographs*. Integrative Medicine Communications.
32. World Health Organization. (2004). *WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems*. World Health Organization.
33. Chan, K. (2003). Some aspects of toxic contaminants in herbal medicines. *Chemosphere*, 52(9), 1361-1371.
34. Aschwanden, C. (2001). Herbs for health, but how safe are they? *Cell*, 107(4), 411-413.
35. Hossen Mohammed Al-Mahdi Al-Sharif. (2025). Analysis and Evaluation of ARIMA and SARIMA Models Performance in Time Series Forecasting: An Applied Study. Libyan Journal of Medical and Applied Sciences, 3(2), 146–157. https://doi.org/10.64943/ljmas.v3i2.89
36. Hu, R., et al. (2016). Network pharmacology-based research on the multi-target mechanisms of natural compounds. *Drug Discovery Today*, 21(7), 1112-1119.
37. Li, F. S., & Weng, J. K. (2017). Demystifying traditional herbal medicine with modern approaches. *Nature Plants*, 3(8), 17109.
38. Williamson, E. M. (2001). Synergy and other interactions in phytomedicine. *Phytomedicine*, 8(5), 401-409.
39. Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364.
40. Intisar A. F. El Sharaa, Salwa Younis Salem Rahil, & Khadija S. El-Turki. (2025). Determination of Some Heavy Metals in Some Cosmetic Products (Foundation, Blusher, and Face Powder) By Atomic Absorption Spectrometer. Libyan Journal of Medical and Applied Sciences, 3(3), 107–114. https://doi.org/10.64943/ljmas.v3i3.155
41. Sarris, J., et al. (2012). Plant-based medicines for anxiety disorders: Part 1. *CNS Drugs*, 26(3), 211-225.
42. Barnes, J., Anderson, L. A., & Phillipson, J. D. (2007). *Herbal medicines* (3rd ed.). Pharmaceutical Press.
43. World Health Organization. (2011). *Quality control methods for herbal materials*. World Health Organization.
44. Zhang, A. L., et al. (2015). Evidence-based Chinese medicine: Clinical applications and challenges. *Evidence-Based Complementary and Alternative Medicine*, 2015, 829023.
45. D'Incalci, M., et al. (2005). The importance of natural products in modern oncology. *European Journal of Cancer*, 41(14), 2179-2185.
46. Kroll, D. J. (2001). Botanical dietary supplements and cancer: Questions and answers. *Integrative Cancer Therapies*, 1(2), 110-118.
47. Atanasov, A. G., et al. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnology Advances*, 33(8), 1582-1614.

48. Vlietinck, A., et al. (1998). Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. *Planta Medica*, 64(2), 97-109.
49. World Health Organization. (2007). *WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants*. World Health Organization.
50. Smillie, T. J., & Khan, I. A. (2010). A comprehensive approach to identifying botanical materials. *Clinical Pharmacology & Therapeutics*, 87(2), 175-186.

التحول المعرفي والعلاجي من الأدوية المصنعة إلى الطب النباتي والعلاجات البديلة: تحليل مقارن للآليات الفيزيولوجية والفعالية السريرية والتأثيرات البينية والمسارات الجزيئية

الملخص

يركز هذا البحث الأكاديمي على التحول الجذري الذي يشهده العالم، حيث يُعاد تقييم الاستخدام السائد للأدوية المصنّعة وتزايد استبدالها أو تعزيزها بالطب النباتي والطب التكميلي/البديل .(CAM) ومن خلال تطبيق إطار تقييم مقارن ومراجعة فسيولوجية-بيئية، تُحلل هذه الورقة البحثية الفعالية العلاجية، والخصائص الجزيئية، والآثار الجانبية، بالإضافة إلى البصمة البيئية لكلا النموذجين الطبيين.

وتشير الأدلة إلى أنه على الرغم من أن الأدوية المصنّعة توفر حلولاً سريعة في الحالات الحادة والإسعافية، إلا أن الاعتماد عليها لفترات طويلة مرتبط بارتفاع معدل حدوث الآثار الجانبية(ADRs) ، وإمكانية رصد التلوث البيئي الدوائي(Ecopharmacovigilance) ، وتزايد خطر مقاومة مضادات الميكروبات .(AMR) في المقابل، أثبتت المستحضرات النباتية فعاليتها العلاجية الشاملة من خلال "تأثير التآزر (Entourage Effect) "وعلم الأدوية الشبكي متعدد الأهداف (Multi-target Network Pharmacology)، وتتميز بانخفاض سميتها الحادة. ومع ذلك، تواجه الأدوية النباتية صعوبات تتعلق بتوحيد المعايير بين الدفعات وتضارب اللوائح التنظيمية. تُبرز هذه الورقة الحاجة إلى تطوير نموذج "الطب التكاملي" الذي يجمع بين سلامة الطب النباتي وتآزره متعدد الأهداف، وبين دقة المعايير التحليلية والضبط السريري للعلوم الطبية الحديثة